

International Supply Chain Expansion & Approvals During COVID-19 Cellicon Valley '21 Future of Cell and Gene Therapies, May 2021

Amir Hefni, PhD MBA Global Commercial Head, Cell & Gene, Novartis



"We're making the immune system do things it never could ... it's unlike anything the pharmaceutical industry has ever done."


Carl H. June, MD Richard W. Vague Professor of Immunotherapy at the Perelman School of Medicine and Director of the Center for Cellular Immunotherapies at the Abramson Cancer Center, University of Pennsylvania



- The Kymriah Journey: From FDA approval to today
- Our commitment to no queue & broader patient access
- Adapting to the COVID-19 pandemic




Novartis journey of bringing CAR-T cell therapy to patients



Reimagining Medicine

A truly global undertaking to successfully scale up and deliver Kymriah for patients in need

- 7 facilities across 4 continents
- Comprehensive, integrated footprint strengthens the flexibility, resilience and sustainability of the manufacturing and supply chain
- Strong capacity growth (+124% 2019 vs. 2021)
- Manufactured CAR-T cells for >4,500 patients worldwide



Broad geographic footprint for worldwide access to Kymriah

 \checkmark

Approved for r/r pALL and DLBCL in the US, EU, Switzerland, Canada, Australia, and Japan

- >300 qualified treatment centers
- Gradual expansion to ensure patient safety and supply


Reimbursement achieved in 28 countries



Additional markets being evaluated to provide greater patient access to Kymriah



COVID-19: Can't Stop, Won't Stop



During COVID-19 Pandemic	Increase Patient Access	Accelerate Capacity Building	Commitment to Partnership
	 Regulatory approvals (Hong Kong, Singapore and Saudi Arabia) Three reimbursements (Romania, Hong Kong & Saudi Arabia) >90 global sites onboarded (25 US, 35 EU, 34 Intl) 	 >10 FDA approved manufacturing updates (capacity, consistency & quality) Two new manufacturing sites (Japan & Australia) 	 Moving apheresis and infusion dates and sites to accommodate patient and site needs Virtual site onboarding Moving fully into e-signatures to avoid delays (including patient support) Travel assistance
	 Benefits of outpatient use, supported by RWE 		programs

U NOVARTIS |


Reimagining Medicine

"Though these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy."*

*Source: Biol Blood Marrow Transplant 26 (2020) 1239-1246

7 | Novartis Cell & Gene Oncology

Update on Kymriah manufacturing




<u>Click here</u> for full Prescribing Information for KYMRIAH® (tisagenlecleucel) suspension for IV infusion, including Boxed WARNING, and Medication Guide.

8 | Novartis Cell & Gene Oncology

Relentless drive to address medical needs through reimagining medicine using our Cell & Gene Platform

Expand access to Kymriah across the globe







External collaborations to deliver Kymriah to patients



"I was given 3 to 6 months to survive, and I'm 16 months in remission...I'm a walking miracle."

Scott McIntyre Patient September 2017

> "Our daughter was going to die, and now she leads a normal life...she's standing right beside me and it's because of this treatment." Tom Whitehead Father of Emily Whitehead



Thank you

אראוראוראוראוראור האוראוראוראוראור אוראוראוראוראוראורא עראוראוראוראוראורא

ארכזורקורקורקורקור ורקורקורקורקורק ארקורקורקורקורקור

マンセインセインセイン יראיולצוולצוולצוולצוול אוולצוולצוולצוול זורדורדורדור